Gilead's New Hep B Treatment Shows Safety Benefit But Is It Enough?

Gilead Sciences Inc. is to file for US and EU approval this quarter of its once-daily treatment for hepatitis B, tenofovir alafenamide (TAF) 25 mg, on the basis of two newly reported Phase III studies.